All Type of News
Korean drugmakers urged to develop first generic versions
In Korea, considered one of Asia's top pharmacy markets, the size is expected to go up 9 percent to almost 12 trillion won this year.
Along with the sizeable jump, the competition between local and global makers wi...
RMS Korea on bumpy road
RMS Korea plans to acquire financially distressed Inyoung Pharm at the end of this year to expand its presence in the domestic drug logistics market.
However, the company has been facing strong challenge from local...
8.7 billion won set aside against tuberculosis
The government will provide Green Cross Corporation with 8.7 billion to help produce BCG vaccine in Korea as part of its efforts to eradicate tuberculosis.
The Ministry of Health, Welfare and Family Affairs has an...
CJ-Henkel Korea team up over household insecticides
It is usual for the nation's two companies to have forged a partnership to strengthen their presence in the market.
CJ Cheil Jedang and Henkel Korea, Korean unit of Germany based Henkel AG, said on December 8 that...
Health functional drinks deemed expensive at supermarket
A survey of 20 pharmacies and 20 supermarkets showed that the prices of major four health drinks at supermarket are higher than those at pharmacies.
The Korean Pharmaceutical Association reported that the price dif...
Korea's pharmaceutical pricing system
The government intends not to cut the insurance price of an original drug if a generic product is not launched despite its listing in the eligible health insurance. However, any patent trial to confirm the scope of a ...
Pharmaceutical firms mull ‘no incentive, no gifts’ over OTC products
A number of pharmaceutical companies are considering stopping any incentive or gifts to promote their OTC products from next year.
They believe that such promotional activities may violate the current law.
Most ...
Green Cross to conduct phase III trial for Peramivir
Green Cross Corporation plans to conduct its local phase III trials with peramivir injection, an important potential therapy for both seasonal influenza and pandemic preparedness as the Korea Food and Drug Administrat...
Ildong to co-develop GLP-1 fusion protein formulations with Genexine
Ildong Pharm and Genexine Co., a drug development biotech, entered into a collaboration agreement by signing a contract of the Product co-development.
The contract encompasses co-commercialization of GLP-1 (glucag...
Park Sang-dae named new president for Korea Support Committee for IVIInternational Vaccine Institute (IVI) appointed Kim Park Sang-dae, a honorable professor of Seoul National University, as its third chairman.
Park will succeed two predecesso...
|
